SCHEMBL4053685

SCHEMBL4053685

c1ccc(SCc2nc3ncc(-c4cccs4)cc3[nH]2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP2D6 P10635 1/20 0.46
APOBEC3G Q9HC16 1/20 0.42
PKM P14618 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
LMNA P02545 1/20 0.40
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
KMT2A Q03164 3/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 2/20 0.38
MEN1 O00255 2/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4055054 0.84 NPC1 (0.54) SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4
SCHEMBL4063023 0.82 GAA (0.43) SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4
SCHEMBL13608051 0.82 SMN1; SMN2 (0.46) SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4
SCHEMBL4051334 0.81 NOS3 (0.47) SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4
SCHEMBL4055025 0.81 SMN1; SMN2 (0.47) SMN1; SMN2NPC1RAB9AAPOBEC3GLMNA
SCHEMBL4058739 0.78 NPC1 (0.47) SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4
SCHEMBL4052395 0.77 RAB9A (0.46) SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4
SCHEMBL4055037 0.77 TDP1 (0.65) SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4
SCHEMBL4051893 0.75 PRNP (0.44) SMN1; SMN2NPC1RAB9AAPOBEC3GPKM
SCHEMBL4056022 0.72 NPC1 (0.44) SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B SMN1; SMN2 4289/4885NPC1 4740/4885RAB9A 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.